Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial
Evaluation der klinischen Wirksamkeit eines neuen Palmitoylethanolamid–Equisetum-arvense-Nahrungsergänzungsmittels zur Behandlung chronischer Schmerzen: Ergebnisse einer prospektiven klinischen Studie
Medical Sciences · 03.09.2025 · 13 (3) · 169
DOI: 10.3390/medsci13030169 ↗Auf einen Blick
In einer prospektiven klinischen Studie bei 50 Patient:innen mit chronischen Schmerzen nahm die Schmerzintensität unter einem PEA–Equisetum-arvense-Supplement über 8 Wochen ab. Auch Lebensqualität und Patient:innenzufriedenheit verbesserten sich.
Fragestellung
Wird die Schmerzintensität bei chronischen Schmerzen durch ein orales Supplement aus 600 mg Palmitoylethanolamid und 300 mg Equisetum arvense verbessert?
Methode
Prospektive, einzentige klinische Studie; 50 Patient:innen mit chronischen Schmerzen, behandelt über 8 Wochen in ausschleichendem Regime.
Ergebnisse
NPRS −3,8 Punkte; VRS −2,1 Punkte; p < 0,0001. EQ-5D-5L +35 %; p < 0,0001. Die Gesamtansprechrate lag bei 94 %.
Schlussfolgerung der Autor:innen
Die Ergebnisse unterstützen laut Autor:innen die Verwendung dieser PEA–Equisetum-arvense-Formulierung als sichere, gut verträgliche und potenziell wirksame ergänzende Intervention bei chronischen Schmerzen.
Kernaussagen
- Schmerzintensität nahm unter dem Supplement ab
- Lebensqualität verbesserte sich
- Keine unerwünschten Ereignisse berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie in der Zeitschrift Medical Sciences, online erschienen am 03.09.2025. Verfasst von Marco Invernizzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy. Hauptthemen laut MEDLINE: Palmitic Acids, Ethanolamines, Chronic Pain, Dietary Supplements. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agave Group srl, Noivita srls, MUR–M4C2 1.5 of the PNNR.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Chronic pain represents a major therapeutic challenge due to the limited efficacy and tolerability of conventional pharmacological treatments. Equisetum arvense L., a medicinal plant with potent antioxidant properties, and palmitoylethanolamide (PEA), an endogenous fatty acid amide with well-established anti-inflammatory and analgesic effects, are increasingly recognised as promising nutraceutical agents.
Methods
This prospective, single-centre clinical trial aimed to evaluate the efficacy and safety of a novel oral supplement (Assonal®PEA) combining 600 mg of PEA and 300 mg of Equisetum arvense L. in improving the reduction of pain and quality of life in patients with chronic pain, also obtaining information on the patient’s state of satisfaction after the treatment. Fifty patients suffering from chronic pain (low back pain and radiculopathy) for two months were enrolled and received the supplement over eight weeks in a tapered regimen (two tablets daily for two weeks, followed by one tablet daily).
Results
Clinical outcomes were evaluated using validated instruments, including the Numeric Pain Rating Scale (NPRS), Verbal Rating Scale (VRS), Short-Form McGill Pain Questionnaire (SF-MPQ), Global Perceived Effect (GPE), and EuroQol-5D-5L. Results showed a significant decrease in pain intensity (NPRS: −3.8 points; VRS: −2.1 points; p < 0.0001), along with meaningful improvements in patient-perceived benefit, pain descriptors, and quality of life (EQ-5D-5L: +35%; p < 0.0001).
Conclusions
These findings endorse the use of this novel PEA–Equisetum arvense formulation as a safe, well-tolerated, and potentially effective supplementary intervention for managing chronic pain. No adverse events were reported, and the overall response rate reached 94%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
- Translational Medicine, Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Azienda Ospedaliero-Universitaria (AOU) SS, Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
- Department for Sustainable Development and Ecological Transition, University of Piemonte Orientale (UPO), 13100 Vercelli, Italy.
- Noivita Srls, Spin Off, University of Piemonte Orientale (UPO), Strada Privata Curti 7, 28100 Novara, Italy.
- Department of Clinical Nutrition, "Villa Maria" Hospital, 47921 Rimini, Italy.
ORCID-Profile: Marco Invernizzi, Arianna Folli, Domenico Tiso, Francesca Uberti
Förderung
- Agave Group srl
- Noivita srls
- MUR–M4C2 1.5 of the PNNR
Zitieren
APA
Invernizzi, M., Mulè, S., Lippi, L., Galla, R., Folli, A., Ferrari, S., Tiso, D., & Uberti, F. (2025). Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial. Medical Sciences, 13(3), 169. https://doi.org/10.3390/medsci13030169
Vancouver
Invernizzi M, Mulè S, Lippi L, Galla R, Folli A, Ferrari S, et al. Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial. Medical Sciences. 2025;13(3):169. doi:10.3390/medsci13030169
BibTeX
@article{Invernizzi2025,
author = {Invernizzi, Marco and Mulè, Simone and Lippi, Lorenzo and Galla, Rebecca and Folli, Arianna and Ferrari, Sara and Tiso, Domenico and Uberti, Francesca},
title = {Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial},
journal = {Medical Sciences},
year = {2025},
volume = {13},
number = {3},
pages = {169},
doi = {10.3390/medsci13030169}
}
EUVIMED